DK2035029T3 - Peptidforbindelser til behandling af refraktær status epilepticus. - Google Patents

Peptidforbindelser til behandling af refraktær status epilepticus. Download PDF

Info

Publication number
DK2035029T3
DK2035029T3 DK07764678.4T DK07764678T DK2035029T3 DK 2035029 T3 DK2035029 T3 DK 2035029T3 DK 07764678 T DK07764678 T DK 07764678T DK 2035029 T3 DK2035029 T3 DK 2035029T3
Authority
DK
Denmark
Prior art keywords
seizures
pharmaceutical composition
refractory
use according
status epilepticus
Prior art date
Application number
DK07764678.4T
Other languages
English (en)
Inventor
Thomas Stöhr
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36889233&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2035029(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Application granted granted Critical
Publication of DK2035029T3 publication Critical patent/DK2035029T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (22)

1. Farmaceutisk sammensætning til anvendelse i forebyggelse, lindring eller/og behandling af en refraktær epileptisk lidelse, den farmaceutiske sammensætning omfattende en forbindelse, der har formlen (II)
Formet pS| hvor Ar er phenyl, som er usubstitueret eller substitueret med mindst én halo-gruppe; Ri er alkyl indeholdende 1 til 3 carbonatomer, og R3 er -CH2-Q, hvor Q er alkoxy indeholdende 1 til 3 carbonatomer, eller et farmaceutisk acceptabelt salt deraf.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den refraktære epileptiske lidelse er en refraktær status epilepticus, eller/og en lidelse beslægtet med refraktær status epilepticus.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1 eller 2, hvor Ri er methyl.
4. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af krav 1 til 3, hvor Ar er phenyl substitueret med mindst én fluorgruppe.
5. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af krav 1 til 3, hvor Ar er usubstitueret phenyl.
6. Farmaceutisk sammensætning til anvendelse ifølge krav 1 eller 2, hvor forbindelsen er (R)-2-acetamido-N-benzyl-3-methoxy-propionamid; (R)-2-acetamido-N-benzyl-3-ethoxy-propionamid; O-methyl-N-acetyl-D-serin-m-fluorbenzylamid; eller O-methyl-N-acetyl-D-serin-p-fluorbenzylamid.
7. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor forbindelsen er i R-konfigurationen.
8. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af krav 1 til 7, hvor forbindelsen ifølge formel (II) er (R)-2-acetamido-N-benzyl-3-methoxypropionamid eller et farmaceutisk acceptabelt salt deraf.
9. Farmaceutisk sammensætning til anvendelse ifølge krav 8, hvor forbindelsen er (R)-2-acetamido-N-benzyl-3-methoxy-propionamid.
10. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den refraktære epileptiske lidelse er en status epilepticus, et epileptisk anfald, gentagne anfald eller/og et klyngeanfald, som fortsætter i mindst omkring 10 min.
11. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den refraktære epileptiske lidelse er mindst delvist refraktær eller væsentligt refraktær mod lægemidler, som anvendes i behandling af status epilepticus eller/og epilepsi, i særdeleshed mod mindst ét lægemiddel valgt blandt benzodiazepiner, barbiturater, og antiepileptiske lægemidler forskellige fra forbindelserne ifølge krav 1, fortrinsvis valgt blandt diazepam, lorazepam, midazolam, phenobarbital, carbamazepin, phenytoin, fosphe-nytoin, oxcarbazepin, lamotrigin, gabapentin, pregabalin, valproinsyre, pentobarbital, thiopental, propofol og farmaceutisk acceptable salte deraf.
12. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den refraktære epileptiske lidelse omfatter fokale anfald eller/og generaliserede anfald og/eller, hvor den refraktære epileptiske lidelse omfatter konvulsive anfald, såsom tonisk-kloniske, toniske, kloniske, eller myokloniske anfald, eller/og non-konvulsive anfald, såsom absencer eller atoniske anfald og/eller, hvor den refraktære epileptiske lidelse eller en beslægtet lidelse omfatter akut gentagne anfald eller/og klyngeanfald.
13. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den refraktære epileptiske lidelse eller en beslægtet lidelse omfatter akut gentagne anfald.
14. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor lidelsen beslægtet med refraktær status epilepticus er epileptogenese.
15. Farmaceutisk sammensætning omfattende (a) mindst én forbindelse ifølge formel (II) som defineret i et hvilket som helst af krav 1 og 3 til 9, fortrinsvis lacosamid, og (b) mindst én benzodiazepin, fortrinsvis diazepam, lorazepam eller/og midazolam.
16. Farmaceutisk sammensætning ifølge krav 15 til anvendelse i forebyggelse, lindring eller/og behandling af en epileptisk lidelse.
17. Farmaceutisk sammensætning til anvendelse i forebyggelsen, lindringen eller/og behandlingen af epileptogenese, sammensætningen omfattende mindst én forbindelse, der har formlen (II)
Ferme! (it) hvor Ar er phenyl, som er usubstitueret eller substitueret med mindst én halogruppe; Ri er alkyl som indeholder 1 til 3 carbonatomer, og R3 er -CFI2-Q, hvor Q er alkoxy, som indeholder 1 til 3 carbonatomer, eller et farmaceutisk acceptabelt salt deraf.
18. Farmaceutisk sammensætning til anvendelse ifølge krav 17, hvor epileptogenese er beslægtet med status epilepticus, såsom refraktær status epilepticus.
19. Farmaceutisk sammensætning til anvendelse ifølge krav 17 eller 18, hvor epilep-togenesen indbefatter udvikling af epilepsi, såsom kronisk epilepsi, eller en epileptisk lidelse valgt blandt status epilepticus, et epileptisk anfald, gentagne anfald eller/og et klyngeanfald, som fortsætter i mindst omkring 10 min.
20. Farmaceutisk sammensætning til anvendelse ifølge krav 19, hvor den epileptiske lidelse omfatter fokale anfald eller/og generaliserede anfald og/eller, hvor den epileptiske lidelse omfatter konvulsive anfald, såsom tonisk-kloniske, toniske, kloniske, eller myokloni-ske anfald eller/og non-konvulsive anfald såsom absencer eller atoniske anfald eller/og, hvor den epileptiske lidelse eller en beslægtet lidelse omfatter akut gentagne anfald eller/og klyngeanfald.
21. Farmaceutisk sammensætning til anvendelse ifølge krav 19 eller 20, hvor den epileptiske lidelse eller en beslægtet lidelse omfatter akut gentagne anfald
22. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 17 til 21, hvor forbindelsen ifølge formel (II) er lacosamid.
DK07764678.4T 2006-06-15 2007-06-15 Peptidforbindelser til behandling af refraktær status epilepticus. DK2035029T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81396706P 2006-06-15 2006-06-15
EP06013655A EP1873527A1 (en) 2006-06-30 2006-06-30 Method for identifying CRMP modulators
PCT/EP2007/005306 WO2007144196A2 (en) 2006-06-15 2007-06-15 Peptide compounds for treating refractory status epilepticus

Publications (1)

Publication Number Publication Date
DK2035029T3 true DK2035029T3 (da) 2017-01-23

Family

ID=36889233

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07764678.4T DK2035029T3 (da) 2006-06-15 2007-06-15 Peptidforbindelser til behandling af refraktær status epilepticus.

Country Status (21)

Country Link
US (3) US20100273714A1 (da)
EP (2) EP1873527A1 (da)
JP (1) JP5795145B2 (da)
KR (2) KR101517133B1 (da)
CN (3) CN101636180B (da)
AR (1) AR061475A1 (da)
AU (1) AU2007260208B2 (da)
BR (1) BRPI0713702A2 (da)
CA (1) CA2651684C (da)
CY (1) CY1118523T1 (da)
DK (1) DK2035029T3 (da)
EA (1) EA018607B1 (da)
ES (1) ES2613931T3 (da)
HU (1) HUE033180T2 (da)
LT (1) LT2035029T (da)
MX (1) MX2008015951A (da)
PL (1) PL2035029T3 (da)
PT (1) PT2035029T (da)
SI (1) SI2035029T1 (da)
TW (1) TWI422384B (da)
WO (1) WO2007144196A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60100055T2 (de) * 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1734980A1 (en) * 2004-04-16 2006-12-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
EP2037965B1 (en) * 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2378291A1 (en) 2010-04-15 2011-10-19 UCB Pharma GmbH Lacosamide detection assay
NZ610701A (en) 2010-12-02 2015-06-26 Ucb Pharma Gmbh Once daily formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
CN108593926A (zh) * 2011-09-14 2018-09-28 促进军事医学的亨利·M·杰克逊基金会公司 检测和监测用于ptsd的诊断生物标志物以及区分***式与非***式障碍的方法和试剂盒
WO2017097311A1 (en) * 2015-12-11 2017-06-15 Aarhus Universitet Rufinamide for use in the treatment of myotonia
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN116731101A (zh) 2016-06-01 2023-09-12 雅斯娜 用于治疗多种疾病的n-己酸-l-酪氨酸-l-异亮氨酸-(6)-氨基己酰胺的衍生物
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023178250A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of tuberous sclerosis with mirdametinib

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US813967A (en) 1905-07-27 1906-02-27 John W Hart Self-igniting match-safe.
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
ES2218024T3 (es) 1996-03-15 2004-11-16 Research Corporation Technologies, Inc Derivados de aminoacido enantiomerico anticonvulsionante.
DE60006618T2 (de) * 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
GB9926898D0 (en) * 1999-11-12 2000-01-12 School Of Earth & Environmenta Calcium silicate sorbents
SI1311256T1 (sl) * 2000-08-17 2005-12-31 Teva Pharma Uporaba derivatov amidov valprojske kisline in amidov 2-valproenske kisline za zdravljenje ali preprecevanje bolecin in/ali glavobolnih motenj
US20020119944A1 (en) * 2000-11-09 2002-08-29 Michelle Aguera Use of Ulip-and/or Ulip2 in the treatment of myelin disorders
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
ATE517629T1 (de) * 2001-09-07 2011-08-15 Inst Nat Sante Rech Med Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems
EA013590B1 (ru) * 2003-12-02 2010-06-30 Шварц Фарма Аг Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
EP1541138A1 (en) * 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
EP1734980A1 (en) * 2004-04-16 2006-12-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
CA2595330A1 (en) 2005-01-28 2006-08-03 Schwarz Pharma Ag Spm 927 for add-on therapy of schizophrenia
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP2037965B1 (en) * 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
NZ610701A (en) * 2010-12-02 2015-06-26 Ucb Pharma Gmbh Once daily formulation of lacosamide
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide

Also Published As

Publication number Publication date
CN101636180A (zh) 2010-01-27
AU2007260208A1 (en) 2007-12-21
CA2651684C (en) 2017-09-12
MX2008015951A (es) 2009-01-12
PT2035029T (pt) 2017-02-03
US20140128378A1 (en) 2014-05-08
EP2035029B1 (en) 2016-11-30
ES2613931T3 (es) 2017-05-29
CN101489591B (zh) 2013-09-11
BRPI0713702A2 (pt) 2012-10-30
EA018607B1 (ru) 2013-09-30
JP2009539910A (ja) 2009-11-19
CN101489591A (zh) 2009-07-22
CY1118523T1 (el) 2017-07-12
CN103751157A (zh) 2014-04-30
CN101636180B (zh) 2012-11-28
EA200900021A1 (ru) 2009-06-30
LT2035029T (lt) 2017-02-10
EP2035029A2 (en) 2009-03-18
WO2007144196A3 (en) 2008-08-21
CA2651684A1 (en) 2007-12-21
SI2035029T1 (sl) 2017-03-31
KR101517133B1 (ko) 2015-05-04
US20100273714A1 (en) 2010-10-28
WO2007144196A2 (en) 2007-12-21
TW200815024A (en) 2008-04-01
US20140128377A1 (en) 2014-05-08
HUE033180T2 (en) 2017-11-28
EP1873527A1 (en) 2008-01-02
AU2007260208B2 (en) 2012-04-12
AR061475A1 (es) 2008-08-27
JP5795145B2 (ja) 2015-10-14
PL2035029T3 (pl) 2017-05-31
TWI422384B (zh) 2014-01-11
KR20090030307A (ko) 2009-03-24
KR20140042926A (ko) 2014-04-07

Similar Documents

Publication Publication Date Title
DK2035029T3 (da) Peptidforbindelser til behandling af refraktær status epilepticus.
TWI397417B (zh) 具有協同抗驚厥功效之醫藥組成物
CN101466390B (zh) 用于治疗难治性癫痫持续状态的肽类化合物
US6417184B1 (en) Triple drug therapy for the treatment and prevention of acute or chronic pain
US20090018197A1 (en) Methods for treating status epilepticus and related conditions
EP1737437A1 (en) Novel use of peptide compounds for treating pain in painful diabetic neuropathy
CA2521274A1 (en) Combinations comprising anti-epileptic drugs for the treatment of neurological disorders